Prognostic significance of p27Kip1 expression in bladder cancer

Farhang Rabbani, Theresa Koppie, Elizabeth Charytonowicz, Marija Drobnjak, Bernard H. Bochner, Carlos Cordon-Cardo

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

OBJECTIVE: To define the prognostic significance of p27Kip1 expression in bladder cancer for overall, disease-specific, metastasis-free and pelvic recurrence-free survival, and to identify clinical and pathological correlates of p27Kip1 immunophenotypes. PATIENTS AND METHODS: Tumour samples from 128 evaluable patients with bladder cancer were assessed by immunohistochemistry for p27Kip1 and E2F-1 expression. Immunoreactivity of p27Kip1 was correlated with clinicopathological variables, E2F-1 immunoreactivity, and outcome. Multivariate analysis was used to assess predictors of outcome. The median follow-up was 30.9 months overall and 105.7 months in the 32 patients alive at the last follow-up. RESULTS: The fraction of tumour cells with p27Kip1 nuclear immunoreactivity was Kip1 reactivity (P = 0.047 and 0.011, respectively). On multivariate analysis, the percentage p27Kip1 reactivity was a significant independent predictor of pelvic recurrence (P = 0.017), progression to metastases (P = 0.046), death from disease (P = 0.008), and death from any cause (P = 0.017), with a low expression portending a worse prognosis. Suspicion of vascular invasion was a significant independent predictor of progression to metastases (P = 0.002), death from disease, and death from any cause (both P <0.001). Lymph node involvement was a significant independent predictor of progression to metastases (P = 0.006). CONCLUSIONS: Low expression of p27Kip1 was a significant independent predictor of pelvic recurrence, progression to metastasis, death from disease and death from any cause, in patients with bladder cancer.

Original languageEnglish (US)
Pages (from-to)259-263
Number of pages5
JournalBJU International
Volume100
Issue number2
DOIs
StatePublished - Aug 2007
Externally publishedYes

Fingerprint

Urinary Bladder Neoplasms
Neoplasm Metastasis
Cause of Death
Recurrence
Multivariate Analysis
Blood Vessels
Neoplasms
Lymph Nodes
Immunohistochemistry
Survival

Keywords

  • Bladder neoplasms
  • Immunohistochemistry
  • p27
  • Tumour suppressor gene

ASJC Scopus subject areas

  • Urology

Cite this

Rabbani, F., Koppie, T., Charytonowicz, E., Drobnjak, M., Bochner, B. H., & Cordon-Cardo, C. (2007). Prognostic significance of p27Kip1 expression in bladder cancer. BJU International, 100(2), 259-263. https://doi.org/10.1111/j.1464-410X.2007.06927.x

Prognostic significance of p27Kip1 expression in bladder cancer. / Rabbani, Farhang; Koppie, Theresa; Charytonowicz, Elizabeth; Drobnjak, Marija; Bochner, Bernard H.; Cordon-Cardo, Carlos.

In: BJU International, Vol. 100, No. 2, 08.2007, p. 259-263.

Research output: Contribution to journalArticle

Rabbani, F, Koppie, T, Charytonowicz, E, Drobnjak, M, Bochner, BH & Cordon-Cardo, C 2007, 'Prognostic significance of p27Kip1 expression in bladder cancer', BJU International, vol. 100, no. 2, pp. 259-263. https://doi.org/10.1111/j.1464-410X.2007.06927.x
Rabbani F, Koppie T, Charytonowicz E, Drobnjak M, Bochner BH, Cordon-Cardo C. Prognostic significance of p27Kip1 expression in bladder cancer. BJU International. 2007 Aug;100(2):259-263. https://doi.org/10.1111/j.1464-410X.2007.06927.x
Rabbani, Farhang ; Koppie, Theresa ; Charytonowicz, Elizabeth ; Drobnjak, Marija ; Bochner, Bernard H. ; Cordon-Cardo, Carlos. / Prognostic significance of p27Kip1 expression in bladder cancer. In: BJU International. 2007 ; Vol. 100, No. 2. pp. 259-263.
@article{28b400c9397b4100afe25ea1fe8a7ffb,
title = "Prognostic significance of p27Kip1 expression in bladder cancer",
abstract = "OBJECTIVE: To define the prognostic significance of p27Kip1 expression in bladder cancer for overall, disease-specific, metastasis-free and pelvic recurrence-free survival, and to identify clinical and pathological correlates of p27Kip1 immunophenotypes. PATIENTS AND METHODS: Tumour samples from 128 evaluable patients with bladder cancer were assessed by immunohistochemistry for p27Kip1 and E2F-1 expression. Immunoreactivity of p27Kip1 was correlated with clinicopathological variables, E2F-1 immunoreactivity, and outcome. Multivariate analysis was used to assess predictors of outcome. The median follow-up was 30.9 months overall and 105.7 months in the 32 patients alive at the last follow-up. RESULTS: The fraction of tumour cells with p27Kip1 nuclear immunoreactivity was Kip1 reactivity (P = 0.047 and 0.011, respectively). On multivariate analysis, the percentage p27Kip1 reactivity was a significant independent predictor of pelvic recurrence (P = 0.017), progression to metastases (P = 0.046), death from disease (P = 0.008), and death from any cause (P = 0.017), with a low expression portending a worse prognosis. Suspicion of vascular invasion was a significant independent predictor of progression to metastases (P = 0.002), death from disease, and death from any cause (both P <0.001). Lymph node involvement was a significant independent predictor of progression to metastases (P = 0.006). CONCLUSIONS: Low expression of p27Kip1 was a significant independent predictor of pelvic recurrence, progression to metastasis, death from disease and death from any cause, in patients with bladder cancer.",
keywords = "Bladder neoplasms, Immunohistochemistry, p27, Tumour suppressor gene",
author = "Farhang Rabbani and Theresa Koppie and Elizabeth Charytonowicz and Marija Drobnjak and Bochner, {Bernard H.} and Carlos Cordon-Cardo",
year = "2007",
month = "8",
doi = "10.1111/j.1464-410X.2007.06927.x",
language = "English (US)",
volume = "100",
pages = "259--263",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Prognostic significance of p27Kip1 expression in bladder cancer

AU - Rabbani, Farhang

AU - Koppie, Theresa

AU - Charytonowicz, Elizabeth

AU - Drobnjak, Marija

AU - Bochner, Bernard H.

AU - Cordon-Cardo, Carlos

PY - 2007/8

Y1 - 2007/8

N2 - OBJECTIVE: To define the prognostic significance of p27Kip1 expression in bladder cancer for overall, disease-specific, metastasis-free and pelvic recurrence-free survival, and to identify clinical and pathological correlates of p27Kip1 immunophenotypes. PATIENTS AND METHODS: Tumour samples from 128 evaluable patients with bladder cancer were assessed by immunohistochemistry for p27Kip1 and E2F-1 expression. Immunoreactivity of p27Kip1 was correlated with clinicopathological variables, E2F-1 immunoreactivity, and outcome. Multivariate analysis was used to assess predictors of outcome. The median follow-up was 30.9 months overall and 105.7 months in the 32 patients alive at the last follow-up. RESULTS: The fraction of tumour cells with p27Kip1 nuclear immunoreactivity was Kip1 reactivity (P = 0.047 and 0.011, respectively). On multivariate analysis, the percentage p27Kip1 reactivity was a significant independent predictor of pelvic recurrence (P = 0.017), progression to metastases (P = 0.046), death from disease (P = 0.008), and death from any cause (P = 0.017), with a low expression portending a worse prognosis. Suspicion of vascular invasion was a significant independent predictor of progression to metastases (P = 0.002), death from disease, and death from any cause (both P <0.001). Lymph node involvement was a significant independent predictor of progression to metastases (P = 0.006). CONCLUSIONS: Low expression of p27Kip1 was a significant independent predictor of pelvic recurrence, progression to metastasis, death from disease and death from any cause, in patients with bladder cancer.

AB - OBJECTIVE: To define the prognostic significance of p27Kip1 expression in bladder cancer for overall, disease-specific, metastasis-free and pelvic recurrence-free survival, and to identify clinical and pathological correlates of p27Kip1 immunophenotypes. PATIENTS AND METHODS: Tumour samples from 128 evaluable patients with bladder cancer were assessed by immunohistochemistry for p27Kip1 and E2F-1 expression. Immunoreactivity of p27Kip1 was correlated with clinicopathological variables, E2F-1 immunoreactivity, and outcome. Multivariate analysis was used to assess predictors of outcome. The median follow-up was 30.9 months overall and 105.7 months in the 32 patients alive at the last follow-up. RESULTS: The fraction of tumour cells with p27Kip1 nuclear immunoreactivity was Kip1 reactivity (P = 0.047 and 0.011, respectively). On multivariate analysis, the percentage p27Kip1 reactivity was a significant independent predictor of pelvic recurrence (P = 0.017), progression to metastases (P = 0.046), death from disease (P = 0.008), and death from any cause (P = 0.017), with a low expression portending a worse prognosis. Suspicion of vascular invasion was a significant independent predictor of progression to metastases (P = 0.002), death from disease, and death from any cause (both P <0.001). Lymph node involvement was a significant independent predictor of progression to metastases (P = 0.006). CONCLUSIONS: Low expression of p27Kip1 was a significant independent predictor of pelvic recurrence, progression to metastasis, death from disease and death from any cause, in patients with bladder cancer.

KW - Bladder neoplasms

KW - Immunohistochemistry

KW - p27

KW - Tumour suppressor gene

UR - http://www.scopus.com/inward/record.url?scp=34447122807&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447122807&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2007.06927.x

DO - 10.1111/j.1464-410X.2007.06927.x

M3 - Article

C2 - 17555476

AN - SCOPUS:34447122807

VL - 100

SP - 259

EP - 263

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 2

ER -